+47%, +16%, +6% — 3 Quiet Movers Breaking Out

July 28, 2025

Earlier this month we spotlighted three names that were overlooked — each with defined entry zones, catalysts, and medium-term upside potential.

As of today, all three have begun to move.

Here's the breakdown 👇

🚐 Thor Industries (THO)

THO dipped into our buy zone shortly after we flagged it — then bounced. With insiders buying, demand stabilizing, and a major buyback program underway, this one’s showing strength in a weak discretionary tape.

  • Entry Range Highlighted: $88–92

  • Current Price: ~$93.80

  • Move Since Watchlist: +2–6%

📌 Watch for: Earnings trends, additional insider activity
🎯 Target Zone: $110–120

Our take: Quiet strength. If macro holds up, this can grind higher into Q4.

💊 Ardelyx (ARDX)

Ardelyx continues to trade off key support, but isn’t yet in full breakout mode. While insider buying and improving reimbursement signals support the thesis, follow-through and volume are still developing.

  • Entry Range Highlighted: $3.70–4.00

  • Current Price: ~$4.29

  • Move Since Watchlist: approximately +7–16%

📌 Watch for: Q2 revenue release, formulary coverage gains
🎯 Target Zone: $10–15

Our take: Holding near entry zone — upside potential intact, but needs execution to lift further.

🧬 Nuvation Bio (NUVB)

NUVB is showing more decisive movement, trading well above the entry range after the CEO’s sizeable share purchase. Volume remains modest, but price is clearly rejecting the lows.

  • Entry Range Highlighted: $1.70–2.00

  • Current Price: ~$2.50

  • Move Since Watchlist: approximately +25–47%

📌 Watch for: Trial updates, further insider activity
🎯 Target Zone: $5–7

Our take: Early, speculative, but insider conviction and price strength give this biotech setup staying power.

🚀 The Big Picture

Each stock respected its defined entry zone and has begun to show movement.

Time and catalysts may determine follow-on strength, but for now, setups are developing as expected.

More of these in the pipeline for our premium members — Every. Single. Week.

StocksTrades.AI Newsletter

Disclaimer: This email is for informational purposes only and does not constitute investment advice. Please conduct your own due diligence before investing.